| Auroprost |
|
|
 |
 |
|
| Latanoprost 0.005% w/v eye drops |
| Product Description: |
| Auroprost is a sterile ophthalmic solution containing 0.005% Latanoprost. It is classified under
elevated intraocular pressure prostaglandin F2 alpha analogue. |
|
 |
| Product features: |
 |
Increases trabecular meshwork outflow |
|
Outflow facility increased by at least 67% |
|
US FDA approved 1st line therapy in glaucoma management |
|
Proven efficacy by 35% (8.9 mmHg) drop in IOP |
|
Proven safety and superior ocular tolerability amongst Prostaglandin analogues |
|
Provides sustained long term IOP control |
|
|
|
| Mechanism of action |
| Auroprost is a prostanoid selective FP receptor agonist which is believed to reduce the intraocular
pressure by increasing the outflow of aqueous humor. Studies in animals and man suggest that the
main mechanism of action is increased uveoscleral outflow. |
|
| Indications: |
| Auroprost sterile ophthalmic solution is indicated for the reduction of elevated intraocular pressure
in patients with open angle glaucoma and ocular hypertension who are intolerant of other
Intraocular pressure lowering medications or insufficiently responsive to another intraocular
pressure lowering medication. |
|
| Contraindications: |
| Known hypersensitivity to Latanoprost, benzalkonium chloride or any other ingredients in this
Product |
|
| Supply |
| Available in 2.5ml in a 3 piece, white opaque, Pre-pierced plastic container |
|
|
